Table 2.
Summary of ABSSSI characteristics (ITT population)
| Characteristic | Delafloxacin, N = 331 | Vancomycin + aztreonam, N = 329 |
|---|---|---|
| ABSSSI category, n (%) | ||
| cellulitis/erysipelas | 128 (38.7) | 128 (38.9) |
| wound infection | 116 (35.0) | 116 (35.3) |
| major cutaneous abscess | 84 (25.4) | 83 (25.2) |
| burn infection | 3 (0.9) | 2 (0.6) |
| Erythema size (cm2; digital), mean ± SD (IQR) | 294.8 ±308.34 (121.5–332.7) | 319.1 ±314.03 (130.2–385.7) |
| Induration size (cm2; digital), mean ± SD (IQR) | 94.1 ±208.66 (22.3–94.8) | 120.7 ±219.6 (26.2–121.6) |
| Systemic signs, n (%) | ||
| lymph node enlargement | 285 (86.1) | 287 (87.2) |
| elevated C-reactive protein, >10× ULN | 131 (39.6) | 136 (41.3) |
| elevated white blood count, ≥10 000 cells/μL | 159 (48.0) | 165 (50.2) |
| fever, ≥38 °C | 78 (23.6) | 63 (19.1) |
| lymphangitis | 68 (20.5) | 55 (16.7) |
| Bacteraemia, n (%) | 6 (1.8) | 9 (2.7) |
| Local signs, n (%) | ||
| erythema/extension of redness | 329 (99.4) | 328 (99.7) |
| heat/localized warmth | 328 (99.1) | 326 (99.1) |
| pain/tenderness | 328 (99.1) | 327 (99.4) |
| swelling/induration | 323 (97.6) | 324 (98.5) |
| drainage/discharge | 209 (63.1) | 207 (62.9) |
| fluctuance | 175 (52.9) | 179 (54.4) |
| Pathogens identified at baseline (MITT), n (%)a | ||
| S. aureusb | 159 (65.4) | 165 (66.8) |
| MRSA | 78 (32.1) | 91 (36.8) |
| MSSA | 82 (33.7) | 74 (30.0) |
a
Patients with baseline pathogens: N = 243 for delafloxacin and N = 247 for vancomycin/aztreonam.
b
Patients with both MRSA and MSSA were counted only once. Percentages based on number of patients with baseline pathogens.